PARTICIPATING MEMBERS

- Philipps-Universität Marburg // Marburg, Germany
- PolyGene AG // Rümlang, Switzerland
- Klinikum Rechts der Isar der Technischen Universität München // Munich, Germany
- Institut für Bioprozess- und Analysenmess-technik e.V. // Heilbad Heiligenstadt, Germany
- Experimentelle Pharmakologie und Onkologie Berlin-Buch GmbH // Berlin, Germany
- Universita Degli Studi di Verona // Verona, Italy
- CeGaT GmbH // Tübingen, Germany
- Universität Ulm // Ulm, Germany
- concentris research management gmbh // Fürstenfeldbruck, Germany
- MIMETAS BV // Leiden, The Netherlands
- Universität Leiden // Leiden, The Netherlands
- Queen Mary University of London // London, United Kingdom

KEY DATA FOR CAM-PAC

<table>
<thead>
<tr>
<th>Name of study</th>
<th>CAM-PaC</th>
</tr>
</thead>
<tbody>
<tr>
<td>Start date</td>
<td>1.11.2013</td>
</tr>
<tr>
<td>Duration time</td>
<td>60 months</td>
</tr>
<tr>
<td>EC contribution</td>
<td>11,193,108 Euro</td>
</tr>
<tr>
<td>Grant agreement no</td>
<td>602783</td>
</tr>
<tr>
<td>Website</td>
<td><a href="http://www.cam-pac.eu">www.cam-pac.eu</a></td>
</tr>
</tbody>
</table>

CONTACT

KEY CONTACTS FOR EMTICS

Prof. Dr. Thomas Gress & PD Dr. Malte Buchholz
Philipps-University of Marburg, Dept. of Gastroenterology
Marburg, Germany

PROJECT OFFICE

Dr. Sara Stöber
concentris research management gmbh
Fürstenfeldbruck, Germany

This project has received funding from the European Union’s Seventh Framework Programme for research, technological development and demonstration under grant agreement no 602783.
WHAT IS CAM-PAC?

CAM-PaC is an international research consortium funded by the European Union’s Seventh Framework Programme for research, technological development and demonstration. CAM-PaC’s mission within the five-year duration of the project is to contribute to solving the socioeconomic and health challenges imposed by one of the most deadliest forms of cancer, Pancreatic Ductal Adenocarcinoma (PDAC).

WHAT IS THE INTENTION OF CAM-PAC?

CAM-PaC will develop novel cellular and animal models, as well as novel strategies to analyse and integrate large scale metabolic, transcriptomic and genetic data from these models, in order to systematically identify, characterise and validate novel targets for therapeutic intervention and bioinformatic models for predictive diagnostics.

The long-term goal of CAM-PaC is to improve survival and reduce suffering of PDAC patients.

WHAT IS CAM-PAC’S STRATEGY?

CAM-PaC brings together experts from different fields and backgrounds in an integrative and systematic approach to develop novel diagnostic and therapeutic tools for clinical PDAC management:

- Technology-centered small and medium enterprises (SMEs)
- Clinical and academic partners with extensive experience in pancreatic cancer molecular biology and management of pancreatic cancer patients
- Technology, data analysis and systems biology experts.